Online inquiry

IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ15947MR)

This product GTTS-WQ15947MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets NGF gene. The antibody can be applied in Osteoarthritis (OA) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Caninized
RefSeq	NM_001194950.1
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	403402
UniProt ID	F1PDQ3

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15947MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ7288MR	IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	FPA-008
GTTS-WQ8035MR	IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	H1H3592P3
GTTS-WQ11421MR	IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	MEDI-8897
GTTS-WQ15582MR	IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	UNII-FFX71LCS5T
GTTS-WQ634MR	IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	7F3com-2H2
GTTS-WQ16015MR	IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	ZW-25
GTTS-WQ12992MR	IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	PEG sTNF-RI
GTTS-WQ11139MR	IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	MDX-1103

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST